Shanghai Junshi Biosciences Co., Ltd.
Symbol: 1877.HK
HKSE
12.6
HKDTržní cena dnes
-5.6777
Poměr P/E
0.0426
Poměr PEG
27.42B
MRK Cap
- 0.00%
Výnos DIV
Shanghai Junshi Biosciences Co., Ltd. (1877-HK) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3778.1 | 5996.9 | 3504.6 | ||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 341.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 483.2 | 517.7 | 1834.8 | ||||||||
balance-sheet.row.inventory | 0 | 538.1 | 599 | 484.6 | ||||||||
balance-sheet.row.other-current-assets | 0 | 744.4 | 91.3 | 7.7 | ||||||||
balance-sheet.row.total-current-assets | 0 | 5549.8 | 7204.9 | 5831.7 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 4253.3 | 3572 | 3421.3 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.long-term-investments | 0 | 1133.1 | 1402.8 | 1123.4 | ||||||||
balance-sheet.row.tax-assets | 0 | 103.4 | 228.4 | 88.5 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 188.4 | 57.6 | 533.9 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 5812.6 | 5371.4 | 5219 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.account-payables | 0 | 247.3 | 281.6 | 196.2 | ||||||||
balance-sheet.row.short-term-debt | 0 | 575.3 | 435.4 | 45.1 | ||||||||
balance-sheet.row.tax-payables | 0 | 59.4 | 35.2 | 80.9 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 1213.2 | 886.2 | 583.1 | ||||||||
Deferred Revenue Non Current | 0 | 181.1 | 121.6 | 118.8 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7.5 | 1057.2 | 1775.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1547.1 | 1007.8 | 701.9 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 53.4 | 90.2 | 127.6 | ||||||||
balance-sheet.row.total-liab | 0 | 4022.3 | 2782 | 2718.5 | ||||||||
balance-sheet.row.preferred-stock | 0 | 0.3 | 68.4 | 0 | ||||||||
balance-sheet.row.common-stock | 0 | 985.7 | 982.9 | 910.8 | ||||||||
balance-sheet.row.retained-earnings | 0 | -9040.8 | -6776.6 | -4388.6 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -142.1 | -68.4 | 0.2 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 15367.7 | 15295.2 | 11438.5 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7170.8 | 9501.4 | 7960.9 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 169.4 | 292.8 | 371.3 | ||||||||
balance-sheet.row.total-equity | 0 | 7340.2 | 9794.3 | 8332.2 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 1133.1 | 1402.8 | 1464.9 | ||||||||
balance-sheet.row.total-debt | 0 | 1788.6 | 1321.6 | 628.2 | ||||||||
balance-sheet.row.net-debt | 0 | -1989.6 | -4675.4 | -2876.4 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -2675.2 | -592.6 | -1669.5 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 293.7 | 262.6 | 151.4 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -173.8 | -5.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 91.9 | 192.8 | 30.7 | |||||||
cash-flows.row.change-in-working-capital | 0 | 687.2 | -318.8 | -13.1 | |||||||
cash-flows.row.account-receivables | 0 | 1229.7 | -770.6 | -482.2 | |||||||
cash-flows.row.inventory | 0 | -136.4 | -154.8 | -167 | |||||||
cash-flows.row.account-payables | 0 | -1229.7 | 770.6 | 482.2 | |||||||
cash-flows.row.other-working-capital | 0 | 823.6 | -163.9 | 153.9 | |||||||
cash-flows.row.other-non-cash-items | 0 | -172.9 | -12 | 7.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.acquisitions-net | 0 | -93.8 | -440.1 | 2.9 | |||||||
cash-flows.row.purchases-of-investments | 0 | -8.5 | -1169.6 | -245.2 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 565.3 | 70.1 | |||||||
cash-flows.row.other-investing-activites | 0 | 28.6 | 49.7 | 66.8 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -467.6 | -1881 | -698 | |||||||
cash-flows.row.debt-repayment | 0 | -113.4 | -793.3 | -401.4 | |||||||
cash-flows.row.common-stock-issued | 0 | 3812.3 | 2150.1 | 4846.9 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 19.2 | 16.7 | 43.2 | |||||||
cash-flows.row.dividends-paid | 0 | -19.2 | -16.7 | -43.2 | |||||||
cash-flows.row.other-financing-activites | 0 | 944.2 | 1308.9 | -32 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 4643 | 2665.7 | 4413.5 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 92.3 | -23.2 | -45.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 2492.3 | 119.6 | 2171 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 5996.9 | 3504.6 | 3385 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3504.6 | 3385 | 1214 | |||||||
cash-flows.row.operating-cash-flow | 0 | -1775.3 | -641.9 | -1498.8 | |||||||
cash-flows.row.capital-expenditure | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.free-cash-flow | 0 | -2169.3 | -1528.1 | -2091.5 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1502.5 | 1453.5 | 4024.8 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 667.3 | 526.3 | 1258.2 | ||||||||
income-statement-row.row.gross-profit | 0 | 835.3 | 927.2 | 2766.7 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.operating-expenses | 0 | 3287.3 | 3644.2 | 3359.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 3954.6 | 4170.4 | 4617.5 | ||||||||
income-statement-row.row.interest-income | 0 | 99.4 | 61 | 31 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 303.2 | 293.7 | 262.6 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -2476 | -2671.6 | -685.3 | ||||||||
income-statement-row.row.income-before-tax | 0 | -2489.9 | -2675.2 | -592.6 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 44 | -93.1 | 135.5 | ||||||||
income-statement-row.row.net-income | 0 | -2281.6 | -2582.1 | -728.2 |
Často kladené otázky
Co je Shanghai Junshi Biosciences Co., Ltd. (1877.HK) celková aktiva?
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) celková aktiva jsou 11362464000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je -0.024.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -2.642.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je -3.152.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -3.231.
Co je Shanghai Junshi Biosciences Co., Ltd. (1877.HK) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -2281624000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 1788567000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 3287276000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.